| Name | Title | Contact Details |
|---|
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
League Inc. is reimagining employee health benefits, and is on a mission to empower people to live healthier, happier lives —every day.
Tivic Health Systems, Inc. is a commercial-phase health technology company delivering non-invasive bioelectronic treatments that provide consumers choice in the treatment of inflammation and related conditions.
BTNX Inc. is a Tilbury, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Milestone Centers Inc. is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Milestone Centers Inc. is based in Pittsburgh, PA. You can find more information on Milestone Centers Inc. at www.aemhmr.org